Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 90.36% is in line with its 5-year average of 92.11%, around the middle of its 5-year range (84.42%–98.82%).
0.17% above its 12-month average of 90.21%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 92.12%.
GROSS MARGIN
90.36%
GROSS MARGIN AVG TTM
90.21%
GROSS MARGIN AVG 3Y
89.23%
GROSS MARGIN AVG 5Y
92.11%
GROSS MARGIN AVG 10Y
-66.14%
GROSS MARGIN AVG 15Y
93.48%
GROSS MARGIN AVG 20Y
88.79%
CURRENT VS TTM AVG
+0.17%
CURRENT VS 3Y AVG
+1.27%
CURRENT VS 5Y AVG
-1.90%
CURRENT VS 10Y AVG
+236.61%
CURRENT VS 15Y AVG
-3.34%
CURRENT VS 20Y AVG
+1.77%
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
+110.53%
vs the sector median at left
Aurinia Pharmaceuticals Inc.
Market Cap
$1.99B
Gross Margin
90.36%
TTM Avg
90.21%
3Y Avg
89.23%
5Y Avg
92.11%
Market Cap
$2.00B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.01B
Gross Margin
86.13%
TTM Avg
85.03%
3Y Avg
84.60%
5Y Avg
84.81%
Market Cap
$2.03B
Gross Margin
97.82%
TTM Avg
97.53%
3Y Avg
97.80%
5Y Avg
96.20%
Market Cap
$1.94B
Gross Margin
70.49%
TTM Avg
67.64%
3Y Avg
66.50%
5Y Avg
65.90%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $1.99B | 90.36% | 90.21% | 89.23% | 92.11% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.00B | 0.00% | 0.00% | 0.00% | 0.00% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.01B | 86.13% | 85.03% | 84.60% | 84.81% |
| Immunome, Inc. (IMNM)vs › | $1.98B | 57.43% | 78.72% | 64.36% | 42.91% |
| AxoGen, Inc. (AXGN)vs › | $2.01B | 74.56% | 75.05% | 76.31% | 78.00% |
| Azenta, Inc. (AZTA)vs › | $1.98B | 44.05% | 44.96% | 41.63% | 40.93% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | 97.82% | 97.53% | 97.80% | 96.20% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.94B | 70.49% | 67.64% | 66.50% | 65.90% |
| Alvotech (ALVO)vs › | $2.05B | 60.45% | 60.99% | 17.21% | 44.81% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.09B | 100.00% | -1064.88% | -1783.56% | -1442.31% |
Gross Margin
90.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 92.12% |
| 2026-03-31 | 91.63% |
| 2025-12-31 | 89.01% |
| 2025-09-30 | 88.42% |
| 2025-06-30 | 89.84% |
| 2025-03-31 | 86.27% |
| 2024-12-31 | 90.73% |
| 2024-09-30 | 91.10% |
| 2024-06-30 | 84.42% |
| 2024-03-31 | 84.59% |
| 2023-12-31 | 88.04% |
| 2023-09-30 | 87.58% |
| 2023-06-30 | 96.23% |
| 2023-03-31 | 98.78% |
| 2022-12-31 | 95.21% |
| 2022-09-30 | 95.61% |
| 2022-06-30 | 94.33% |
| 2022-03-31 | 98.82% |
| 2021-12-31 | 97.94% |
| 2021-09-30 | 98.27% |
| 2021-06-30 | 95.35% |
| 2021-03-31 | 94.75% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | -45734.48% |
| 2019-09-30 | -7635.22% |
| 2019-06-30 | -38355.17% |
| 2019-03-31 | -35336.67% |
| 2018-12-31 | -37275.86% |
| 2018-09-30 | -2873.87% |
| 2018-06-30 | -36120.69% |
| 2018-03-31 | -29523.33% |
| 2017-12-31 | -27935.48% |
| 2017-09-30 | -37165.52% |
| 2017-06-30 | -2060.18% |
| 2017-03-31 | 96.77% |
| 2016-12-31 | 96.67% |
| 2016-09-30 | 96.77% |
| 2016-06-30 | 98.18% |
| 2016-03-31 | 98.25% |
| 2015-12-31 | 96.49% |
| 2015-09-30 | 98.25% |
| 2015-06-30 | 93.22% |
| 2015-03-31 | 91.94% |
| 2014-12-31 | 88.24% |
| 2014-09-30 | 84.72% |
| 2014-06-30 | 85.92% |
| 2014-03-31 | 88.06% |
| 2013-12-31 | 99.86% |
| 2013-09-30 | -521.32% |
| 2013-06-30 | -434.55% |
| 2013-03-31 | 98.88% |
| 2012-12-31 | 92.33% |
| 2012-09-30 | 89.53% |
| 2012-06-30 | 87.78% |
| 2012-03-31 | 99.67% |
| 2011-12-31 | 88.68% |
| 2011-09-30 | 97.84% |
| 2011-06-30 | 89.87% |
| 2011-03-31 | -12.69% |
| 2010-12-31 | 96.87% |
| 2010-09-30 | 96.69% |
| 2010-06-30 | 99.66% |
| 2010-03-31 | 98.10% |
| 2009-12-31 | 97.65% |
| 2009-09-30 | 95.32% |
| 2009-06-30 | 61.70% |
| 2009-03-31 | 100.00% |
| 2008-12-31 | 266.82% |
| 2008-09-30 | 33.17% |
| 2008-06-30 | 59.11% |
| 2008-03-31 | 54.92% |
| 2007-12-31 | 39.91% |
| 2007-09-30 | 48.00% |
| 2007-06-30 | 61.93% |
| 2007-03-31 | 100.00% |
| 2006-12-31 | 74.07% |
| 2006-09-30 | 69.48% |
| 2006-06-30 | 86.30% |
| 2006-03-31 | 100.00% |
| 2005-12-31 | 100.00% |
| 2005-09-30 | 100.00% |
| 2005-06-30 | 100.00% |
| 2005-03-31 | 100.00% |
| 2004-12-31 | 100.00% |
| 2004-09-30 | 100.00% |
| 2004-06-30 | 100.00% |
| 2004-03-31 | 100.00% |
| 2003-12-31 | 100.00% |
| 2003-09-30 | 100.00% |
| 2003-06-30 | 100.00% |
| 2003-03-31 | 100.00% |
| 2002-12-31 | 60.84% |
| 2002-09-30 | 95.37% |
